newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - DENALI THERAPEUTICS INC

Thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS. Very excited to have members of the team from Denali Therapeutics up here with us. Ryan Watts, Chief Executive Officer. Katie Pang, Chief Commercial Officer. We get to talk about commercial sales, revenues, raising guidance recently. And Alex Shuth, Chief Financial and Operating Officer. Great to see you guys. Great to be here. Thanks, Mike. Yeah. Yeah. So look, 2026 has been a transformative year for Denali. You got your first approval, been launching your product and raising guidance, as I said. And obviously, so much pipeline here, I told my colleagues, we don't have time to go through all six of these programs. So we'll try and keep it focused. But I think obviously, most important, it's critical to talk about the approval and the successful launch of Leia, if I got that right. That's perfect. Perfect, Avleya. And I would love to talk about that. So, Ryan, why don't you take a chance to tell us about how the progress of that launch is going. Maybe Katie could talk a little bit about how that's going as well because you raised guidance. And as I was commenting with Alex, all this has happened, but then the stock goes up and it comes back down. And so we're a littlebit puzzled by that. But maybe you could have the opportunity to tell investors about how The Launch is going to go. Yeah, absolutely. Great to be here, Mike. Thanks for the invitation. Love being here in London. And just a quick introduction, and I will hand it to Katie on the launch. As you pointed out, a transformative year. And probably the simplest way to describe Denali now is that we have a product in Avalia that validates our platform, the transport vehicle platform, which then enables our pipeline. And so I think my sense is, first of all, from a company perspective, it's been an extraordinary year. It's really exciting to launch a product. And especially many of the scientists who invented the transport vehicle, who have been involved in its development, and now ultimately in its launch, have been with us now for the 11 years of our existence. And what we're seeing is just incredible experience in the patient community. And I think that's most exciting to see the impact that Avalaya is having. And in addition to that, now knowing that we can take our platform and apply it to other products. And I think the question is, how big can Hunter be? How big can hunter and Sam Filippo together be? And obviously, this platform is not just about treating enzyme replacement therapies or replacing enzyme replacement therapy with molecules that can cross the blood-brain barrier or improve delivery to brain or muscle, but it's also about using this technology in Alzheimer's disease. We'll get to those, because those are multi-multi-billion. Exactly. And more and more data is coming out proving it works. So, in terms of the launch, I'm going to hand it to Katie to give us an update. Great. I mean, specifically on the launch we're super pleased with the trajectory. We reported close to $18 million last quarter, which was significantly higher than our $10 to $12 million in guidance, and largely that is driven by the acceleration of payer access. And so, we were able to unlock commercial and Medicaid payment very quickly. In addition, we had a great bolus of our E2 patients, our clinical trial patients, come on to treatment in Q3, which was much sooner than we expected, and those patients were all at the highest dose. In addition we've heard tremendous feedback from physicians and especially from the families on how well the patients are doing on Avlea, and we also discussed bringing in the S-shaped curve. We talked about rare disease launches having this S-shaped curve, but that we are bringing that inflection in sooner because of the momentum we're seeing behind the launch. And we said, you know, between Q2 and Q3, that's probably not the run rate you expect to see, but we expect strong growth, especially between 2026 and 2027. That inflection is coming, and we're building on a very strong patient base. And generally, in rare disease, persistence is high. So we expect really good, strong growth. So you did $18 million. That was higher than consensus and guidance. You guided for Q4. Yes. Tell us about that guidance because what you said is a lot of this early growth, although I'm not sure you've quantified it, has been patients who've also been able to swap from existing. So of those patients you have, and I guess you could divide the revenues by the price and kind of come up with some patients. We have that estimate. But how much of that is new patients that are swapping from, obviously, Elliprase versus people who are on your drug already? That's an easy swap. Yeah. So it's a great question. So we guided to 30 to 32 million in this coming quarter. And majority, actually, of patients are a switch from Elliprise. From Elliprese. Yes. Because about 95% of patients in MPS2 was treated already with enzyme replacement therapy. and we talked about wanting to be the market leader in our eligible patient population, right? So that would be dominant market share in our pediatric population, but also being able to treat all of the new patients and the physicians would select Avlea to start new patients as well. But the dominant, you know, prevalent patient is on Elaprase, so there's switches. All of our patients are switched. And we've done some estimates, but remind me how many people you think are in the prevalent swap pool that you think you could go after for Hunter in your label? Yeah. So the total U.S. population with Hunter syndrome is 500 patients. And of that, our FDA label makes eligible patients to be 375. And we believe the entire pediatric population is eligible for EVLEA because in thinking about neurologic manifestations, you talk to physicians today and almost all patients at some point in time will develop neurologic manifestations. So preventing it or treating it are really critical to HCPs. So I won't get too far ahead of guidance. I'm not sure you're going to guide an early 27. You could tell me if that's a reasonable or not reasonable expectation, guidance for 27. But would you expect to get a you know majority of those patients 350 plus in 2027 you think that's reasonable so maybe i'll let you address the guidance piece alex um but in terms of our um our goal is absolutely to become the market leader as soon as possible okay which is majority which is majority okay exactly what uh so that is the goal but is that something that's doable in a pretty quick time frame? Yeah, absolutely. And we believe the way the trajectory is going, we believe that next year we can become the market leader in Hunter syndrome to the point on the guidance. So we wanted to provide the market the best picture of how we see the launch going, which is why we decided to provide revenue guidance for the first quarters in 2026. We have not made a decision yet if we continue that guidance going forward, because I think it will become less relevant once we're actually on the trajectory. Okay. All right. quarterly guidance is good. Annual guidance is good. We have our own analyst estimates for that. I think you should be able to get 50% of those patients. So appreciate that. And then just lastly on this, before we get to the meat of some of this pipeline, is tell us about the confirmatory study. My understanding is that the data would be coming, I say next year, but like we're already in 27, but in 2028, and to what extent you feel confident or greater than 50 or 60 or 70% confident that that's going to hit the primary endpoint. As an analyst, I would say if it's close but doesn't hit statistical significance, I don't think the FDA is going to get too bent out of shape about it, but you know, we do want to have statistical significance on a confirmatory study. Yeah, so just a reminder of the COMPASS study design, just briefly. So there's 56 patients split between two cohorts, cohort A, which is focused on really the neurologic manifestations of disease, and cohort B, which is the more systemic manifestation of disease. We designed this study focused on two co-primary endpoints. The first is CSF heparin sulfate, which, of course, we've shown the ability to reduce CSF heparin sulfate by 90-plus percent. That is the approvable endpoint for the accelerated approval. The second co-premary endpoint is actually Vinland. It's actually a composite of the Vinland. There we've also shown and published in the New England Journal improvement in behavior. Also, key secondary endpoints will be like Bailey, which is a measure of cognition in younger patients. And then in the cohort B, we're looking at not just six-minute walk, but also important peripheral biomarkers like urine, heparin, sulfate, liver, and spleen volume. Basically, all of these endpoints, we've shown data before, and we've presented the data in the new England Journal article that was published early this year. So we're confident in the design of the trial. The reality is that it is an ultra-rare disease, and therefore, you can always power these things that you would wish you could power them greater, but we're in, I think, a very strong position. In addition to that, incredible real-world data from the launch of Avalaya. So in terms of timing, the cohort A is the sort of rate-limiting step. All patients will reach a two-year endpoint by the end of next year, as you point out, and therefore it will be 2028. why is this study important? It's important for two reasons. One is expansion of the label, okay, and the second is to be able to file outside the U.S. and I'll call it the last third of the market. So when we think about the market, we're accessing the U。S., and then there is a third ofthe market that we can access right now that we're actively pursuing, and then the last three will be enabled by the Compass data. Okay. Yeah, I mean, it's important because not only does it serve as a confirmatory study, but it also is required because outside of the United States, they do want a randomized controlled study for that. So we've done work around that. I would say I'm not 90% confident. Maybe you can get me 90% confidence, but there is a view that the placebo will continue to decline. Excuse me, the L-aprazole will continue decline, and obviously your drug should offer protection. Therefore, they should have modest or almost no decline. In fact, improvements. Yeah, that's actually key. We've seen significant improvement, and I think for us, the data that we use, there are some natural history data. Actually, there are large studies like the intrathecal LOPRAE study where that data is really helpful to sort of predict, seeing that that particular approach did not reduce neurofilament, which is a key marker of neurodeterioration. You can kind of pool that data, and then, of course, our own phase 1-2 data that increases our confidence in that study. Right. Okay. All right. So we'll look forward to that. That's in first half 28. Now, I would like to go to briefly the Sanfilippo program, because this goes back to your thesis that if it is approved, validates, FDA is all good with the approval, accelerated approval on Hunter, that basically Sanfippo type A should have the same regulatory endpoints and the same heparinsulfate endpoints, and that should be an accelerated filing. Now, I think it's a little bit of a smaller market than Hunter combined. These can be a billion dollars or more, but maybe talk about where you are with Sanfilippo because it's literally the same regulatory filing and the same endpoint. Right. And as you point out, the Hunter filing and Avalaya leading the way. So Sanfippo, there are key similarities and some key differences. So Sanfillipo is actually primarily a neurological disease where Hunter is, you know, much more whole body, including the brain. That being said, there are peripheral manifestations of disease in Sanfilippo, for example, in large liver and spleen. The data that we've presented show normalization of liver and splen, a robust reduction in heparin sulfate with the ability to normalize as well. Those patients that don't normalize, like most enzyme replacement therapies, have usually anti-drug antibodies, so continued dosing or changing the dose regimen. That's what we learned from the first eight patients. That data was presented at World. So to date, that's the most robust data set on biomarkers. By the way, no approved drugs here. That's right. Well, that'S not correct. So there was just a gene therapy approved by Ultragenyx, which was originally developed by Abiona. Okay. And that one shows about 50%, 60% reduction in CSF heparin sulfate. I won't go into more detail, but beyond maybe saying that there may not be an impact, for example, on liver. So there's room for improvement, no doubt. And this particular medicine, Zafi, as we call it, has that ability to robustly reduce heparin sulfate and treat brain, but also body. Right. So they had some data. It wasn't approved. This is a direct injection? It's actually not. So that's an interesting point about it. There are two ways to approach gene therapy in the lysosomal storage diseases. There are, in Hunter, there was a direct infection in the brain. But for Sanfilippo, this is an AAV9-delivered system. Okay. Okay. And again, this would be like, okay, well, they have some data, but that's a one-time therapy. Yours is an enzyme replacement therapy, much more traditional approach, has stronger data. Yeah. And both peripheral and CNS effect. That's right. And I think the key here is, I mean, the way to look at it is when you think of gene therapy, you think about durability and effect size. And the way we view it is it's probably going to be either you go just on Zafi or you add it on top of gene therapy over time. And that's actually how we viewed it as well in Hunter syndrome, where in that case it was injected directly in brain. That program is currently not advancing. Where are you with the status of this program and the potential filing? Yeah, so we've just completed the 49-week portion of the study in September. Database lock is now preparing data we're going to share data at world which is essentially the pivotal data for the bla filing which is really important we're excited about that data uh in february um and and then basically the timing of filing is being driven uh mainly by what we call module through what everyone calls module three which is the uh manufacturing and unlike avalea which we manufactured uh actually outside the u.s uh with lonza we're manufacturing zafi ourselves in our own facility in the U.S., and basically that's going to be our first launch, obviously, from our own facility, and so that's what we're really focused on is being ready for inspection and ready to launch our own commercial product. And part of that is just driving the maximizing cogs and really bringing our manufacturing to the highest level, which when you manufacture a commercial product, that is the highest level. Yeah, look, it's great to have your own in-house manufacturing. That's important. And by the way, could you move Hunter to that as well? So we've thought about that. The issue with moving Hunter is that we're actually, thanks to Katie and a successful launch, we need to scale it up from 2,000 liters, 6,000. And our facility is two 2, 000 liters. So too much detail, but it makes sense for us to stay with Lonzo. They've been a great partner, and we're going to scale that up also in the U.S. For Sanfilippo, your ability to do that obviously improves COGS. There's not a third-party markup that they're taking off of that. It does that, and I'll just also point out, because we're gonna go to the rest of the pipeline. all of our other products, including our Pompei medicine, obviously FTD granule, but our Alzheimer's medicines, we manufacture ourselves now. And so across the board, like elevating our own manufacturing. And I think the way that Alex likes to describe it, Alex, if you want to give more detail, is that we've spent enough on manufacturing for Avlea that we can build our own facility and within one or two products, we can get there. Now, let's talk about the blood-brain shuttle for neurological diseases like Alzheimer's and for Alzheimer's and others. So look, Ryan, we have talked about this for years, right? I've been excited about this because we're talking about multi-billion dollar indications and particularly where taking an antibody and dragging it through the blood-brain shuttle to target things like A-beta or, you know, obviously MAP-T, it makes every sense in the world because it's very difficult with an antibody or an ASO. So this is exactly where your technology platform can shine. Now with tau, in a positive, we had positive phase two data from Biogen, and they have since pushed that to a planned phase three. So I would argue that tau does have cognitive benefits. We can debate the statistical significance and all of these different things, but clearly there's pretty good proof of concept. Tell us about your MAP-T program, and tell us why you think it would be much better than Biogen's naked ASO, and what have we learned from Biogen? Because, by the way, I think there's data this week. I'm not exactly sure. Yeah, today. Did we get the data already yet? But what would you learn from that? If this happens live, just let us know. Okay, just letting us know, we'll webcast it in here. But philosophically, what would we learn from it? The audience knows that the Biogen data is positive trends and overall looks good. Again, I don't want to debate statistical significance, but like what would we, what would you want to learn? And then why is your product going to be better? Yeah. So I'll start with a general comment and then go specifically down to map T. So as you point out, you know, Mike, we've been discussing this for the 11 years of our existence and, and, you Know, with the first FDA approved platform in the transport vehicle, it's perfect for us to use this transport vehicle now to go after different modalities and different therapeutic areas. I will say 11 years ago, I didn't imagine how rewarding it would be to focus on the rare diseases like Hunter and Sanfilippo, and it's become a real area of focus. We can build a real and frankly robust business, which will then fuel our opportunity to go after some of these other areas. The enzyme replacement business can be a billion-dollar business generating free cash flow to support all these others. Yeah, and I think actually if you look at the four enzymes that we have in addition to Pompe and then obviously G-Case and Gaucher, and we put FDD granule in there as well. I mean, this is four, you know, three to four billion in peak revenue just in those programs alone, which have very high probability. Now, you go back 10 years and then come today and you realize you now have A-beta as a validated target in Alzheimer's. Approved drugs, yes. And you have with approved drugs. And the interesting thing about enzymes, it's unlocking. For Alzheimer's, it is enhancing. And what I mean by that is you have approved drugs, they're standard antibodies, only a fraction of that antibody gets across the blood-brain barrier, but they're slowing neurodegeneration. Now we can dramatically enhance that. That's been shown by others, and we obviously have our own product where we're in phase one right now. With MAP-T, now going very specifically to MAPT, this could be, and I would argue, having worked in the Alzheimer's space also for two decades, both blood- brain barrier and Alzheimer's, that this is the second clinically validated target. That the reason why the data presented in July were confusing was this inverse dose relationship looking at the CDR sum of boxes. But if you look at MMSE and ADAS-COG, those were statistically significant at all doses. And CDRsum of boxes was significant at the low dose and less so not significant atthe mid and the high dose, but some complications with intrathecal delivery. So you can either interpret it as you need to get a certain amount of tau reduction to optimize the benefit, or there is some limitation to intrathecal delivery. You can interpret it either way. Well, what do you mean by that point? Because this would be, overall, I just want to say that Wall Street looked at the data. We think there's some positive trends. I got to be honest, they don't have a lot of patients for looking at Alzheimer's data these days, focused on a million other things. And it worked at the low dose, didn't work at the higher doses. but every other endpoint besides CDR sum of the boxes has some pretty strong trends. What are you saying? I'll just add one sort of corrective note to that. It worked statistically significant at the low, medium, and high dose for ADAS-COG and for MMSC. So in the CDRsum of the Boxes, which was the primary endpoint, it was the low dose that showed the greatest benefit. And I don't want to go into too much detail because I'm not developing an intrathecal medicine. I should talk about the OTV, which is the oligotransport vehicle. But the idea, like, why does tau work? Yeah, and I think that, so why does tao work? If you look at all the data, basically tau is downstream of A-beta. Neurofibrillary tangles and the pathology associated with neurofibrillatory tangles correlates with cognitive decline. So in other words, plaque happens, you know, 20 years before disease. Then you start to develop tangles. Tangles progress as disease progresses. So this is a likely downstream second target. I think very exciting on its own. Also very exciting in combination. with A-beta. So then your program is going to take an ASO. I assume it's pretty similar to the Biogen one, but we're tagging the TFR shuttle to it and dragging the ASO way more efficiently and way more powerfully than a naked antibody. That's right. Intrathecal. Yeah. And I think that the biggest issue is with intrathequal, you have very high concentrations in the spine and you have uneven concentrations inthe brain. When you use the transport vehicle, you get even distribution throughout the entire central nervous system, and that's because you're crossing the capillaries. And that's been well-documented across species. I think that's also translating in human. The best example we have is that eloprase was given intrathecally and did not work, but eloprise given as Avlea robustly works than this. And not only the biomarks translate to clinical benefit, but you're seeing really good clinical outcomes with that approach. And so it's similar with an intrathingal delivery of an ASO. You're going to have this uneven distribution, And that's what the transport vehicle enables is that even knock down. So if we believe that it's going to be better and more efficiently drives a lot more even distribution and a lot more uptake of the ASL through an IV, then through the blood-brain barrier, rather than intrathecal injections, what do you want to see in your phase one? What is the timeline? What are we going to see? For us, I think it's really important to look at the initial biomarkers, so tau reduction. But when you're looking at tau reduction, just like we look at heparin, sulfate, and Hunter, our conclusion is that reduction is even throughout the brain, unlike the intrathecal approach, right? So that's step number one. It's not just a reduction. It's a reduction evenly across. That's right. So you're looking at CSF tau. That will be the first what we look at. The second we'll be looking at, PET tau. That will take longer. So the data that's been presented so far, which is actually pretty interesting, that even with the intratechal, you get a reduction in PET tau, there may be some unevenness to that, obviously, as we've discussed, but that's going to be interesting. That will takes a bit longer to look at that data. And then ultimately, it's clinical benefit. You have to run the trial. So our goal in the phase 1B is to identify the dose that we hit our target knockdown. And let's say, you know, somewhere between 30% and 60%. We don't really know what that range is. All the preclinical data says, you Know, anywhere between 25% and 50% even is really robust in terms of providing a clinical benefit, so you basically, you Know, need to see believable knockdown, and then you need to run the clinical trial where you're looking at cognitive benefit. remind me the numbers biogen has shown how much uh csf knocked down so the low dose is about 40 45 percent and the high dose was about 60 there's not actually surprisingly even though the dose was two and four fold higher there wasn't a big big difference in the town but they're 45 to 60 percent knocked down in the csf that's right uh if you hit that kind of general range your point is that we're also not only having that because but it's more evenly distributed that's exactly Okay. And that's an important biological benefit. And then on pet tau, that is different. Pet tau, you're actually measuring it on an image. We love to see that because pet A beta, I think we all agree that that's very validated. In fact, FDA even counts that as at one point. So how much pet tau reduction do you want to see? Yeah. So a little bit harder to quantify what you expect. That's about a regional accumulation. So tau is interesting because it spreads across regions. So you're looking for essentially halting the spread but you would also love to see a reduction in you know maybe the the originating uh region as well so and what's interesting is the kinetics of that has been different what there was data showing six months there was no change essentially with intrathecal delivery and then they saw a change at two years the more recent data suggests that you can see some change at one year so even though you knock down tau what it what it's doing is there must be an equilibrium with the neurofibrillary tangles. And so when you reduce total tau, you essentially start shifting that and you start to see that neurofiber tangles are probably like unwinding, if you want to call it that. Okay. Okay, a little different than amyloid plaque, because amyli plaque, what you have is microglia that engulf the plaque. So the antibody coats the plaque, and then actually microglial come in and engulf it. So it's very different than the intracellular pathology of neurofibrillation. So the first readout on CSF tau reduction would be when? So that's next year, and that drives dose. So basically, we know what we want to hit. Once you pick that dose, then you're ready to go do the broader clinical studies. We will also look at tau PET, but I'm providing the bookends, which could take as long as two years, as short as one year. No one's shown more rapid tau reduction than a year, but you know, we'll see with the BBB technology. Look, I would argue that having a significant CSF tau reduction and knowing that the drug is getting to where it's going to and it's safe and getting the same type of reductions as Biogen would be that you're at least getting the same biological tau reduction in a much better, more efficient dose because it's IV and not intrathecal, that you can probably push up as much as you can without having any safety issues. you should go right to a phase 2b i you know so why would i want to wait a year or two or even or even a phase two three you know one that's powered enough to look at clinical endpoints and i think that's that's a likely approach okay we obviously are spending a lot of time thinking about how we develop our a beta molecule and our tau molecule okay and we're very invested in alzheimer's disease because we see these platforms specifically the transport vehicle as being transformative to enable sub-Q, to enable robust reduction versus intrathecal? I will look forward to the CSF tau reduction, and I would appreciate and acknowledge that I do think that the timelines are long because we need to go run the clinical studies, and even for biogen, we've got to see if the biogen result is going to be positive. However, in the last couple of minutes, an ATV-A beta to pull an A beta antibody and use that to get rid of plaque to improve Alzheimer's disease is about as validated as ever, because now we have two approved naked antibodies, and no doubt that the Roche trontinamab data, everybody agrees is pretty good. And I got to say, like, okay, well, Wall Street's not paying so much attention, because there's a lot of other things going on in the world, and it's Roche, so no one's trading Roche on this data, but the result should be positive for the trontinamab A-beta shuttle and show pretty strong efficacy and much less aria, that's great. So your drug has a higher probability of success than the tau. So what is the timelines for this? Because not only is Roche-Trontinamib in a phase three, and I think the data's coming first half 28, but others are following you, like Corsana and some of these others. Of course. So, I mean, for us, 2027 is also a key year for the A-Beta program. Let's identify a dose that is safe, well-tolerated, and reduces plaque. That's going to be the key. There is room for improvement on trontinamab around both hematology and specifically around infusion-related reactions. So that's really important. So we'll start with Healthy Volunteer, very quickly go to patients and look at plaque reduction. And there it's identify dose and go. And, you know, I think the other thing is sub-Q. Enabling a sub-Q is going to be key, which at this point, you can do your sub-Iv. That is the goal for our Alzheimer's. So what exactly is the timing on MAP-T, you're in phase one? Yeah, so both MAPT and a beta data 2027. And would you just, because I'm not sure I care about healthy volunteer data. You will have Alzheimer's data? That's the goal as well. 2027, and that would include pet reduction at three months, six months? Yeah, well, we haven't gone into detail on the study design, but pet reduction is the goal there because that's how we 27 Yeah, exactly. I course on another company their dose and they're just gonna show you the trajectory of it And they say see we're on the trajectory trontinamab. We have trontina map. That's not it. Okay. Okay Thank you very much guys a whole lot going on. Thank you for all these updates continued commercial execution and pipeline Very excited about all this in 27. We only got halfway through it. I know get another R&D day coming up. That right and that. Thank you guys very much. Thank you.

Company
DENALI THERAPEUTICS INC
Keywords
DENALI THERAPEUTICS INC